We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept
PRODUCTS / PRODUCT PORTFOLIO
OTHER THERAPEUTIC AREAS

PRODUCT PORTFOLIO

Lesvi's product portfolio comprises CNS pharmaceuticals and nutraceuticals, unique dosage forms and products in other therapeutic areas such as antiemetic, anti-infective, cardiovascular, pain and respiratory diseases.
Product Indication Dosage form Strength
Quetidia® Useful for the management of anxiety disorders Sep 2014
Quetidia® oral solution Useful for the management of anxiety disorders Sep 2017
Rasagiline Parkinson's Tablets 1 mg
Risperidone Psychosis, schizophrenia, bipolar disoder Film-coated tablets 0.5, 1, 2, 3, 4 and 6 mg
Rivaroxaban Thrombosis, stroke Film-coated tablets 10, 15 and 20 mg
Rizatriptan Migraine Orodispersable tablets 5 and 10 mg
Rotigotine Parkinson's Patches 1, 2, 3, 4, 6 and 8 mg/24h
Seripnol® Useful to promote relaxation and sleep Mar 2012
Seripnol® drops Useful to promote relaxation and sleep Apr 2014


Sodium Oxybate Narcolepsy Oral solution 500 mg/ml
Solifenacin Overactive bladder, urinary incontinence Film-coated tablets 5 and 10 mg
Sultiame * Epilepsy, convulsions Film-coated tablets 50, 100 and 200 mg
Tolcapone Parkinson's Film-coated tablets 100 mg
Tranylcypromine Depression Film-coated tablets 10, 20 and 40 mg
Trazodone Depression XR tablets 75 and 150 mg
Triadenor® Useful for the management of depressive disorders Nov 2014
UMP + Folic Acid + B12 Useful for the treatment of spinal syndromes, neuralgias and polyneuropathies Jul 2018
Valproate Epilepsy Oral solution 60 mg/ml and 300 mg/ml
Valsartan Hypertension Film-coated tablets 40, 80, 160 and 320 mg
Valsartan + HCTZ Hypertension Film-coated tablets 80/12.5, 160/12.5/ 320/12.5, 160/25 and 320/25 mg
FDF PRODUCT PORTFOLIO

[*] Differentiated product
[**] Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.


© Neuraxpharm / LESVI. All rights reserved.